Clinical trial · people
Setmelanotide: 80% (POMC) and 45% (LEPR) lost at least 10% weight
Checked against the paper Clinical trialPublished by PepVault
The takeaway
This paper shows setmelanotide's effect in two rare genetic causes of obesity, not in common obesity.
- Kind
- Clinical trial
- Studied in
- People
- Published
- 2020
- Journal
- Lancet Diabetes Endocrinol
What they tested
The teams tested whether setmelanotide reduces weight and hunger in people with severe obesity caused by POMC or LEPR deficiency, rare inherited gene changes in the body's weight-control pathway.
How the study was done
Two single-arm, open-label phase 3 trials (everyone got the drug and knew it) at 10 hospitals enrolled people aged 6 or older: 10 in the POMC trial and 11 in the LEPR trial. After 12 weeks on the drug, those who lost at least 5 kg (or 5% if they weighed under 100 kg) entered an 8-week blinded phase with 4 weeks each of drug and placebo (a dummy shot), then 32 more weeks on the drug.

Model. Individual results vary.
What they found
At about 1 year, 80% of POMC participants and 45% of LEPR participants had lost at least 10% of their starting weight. In participants aged 12 or older who passed the early weight-loss cutoff, the worst-hunger score fell by 27.1% in the POMC trial (7 people) and 43.7% in the LEPR trial (7 people). Injection site reactions happened in everyone, hyperpigmentation (skin darkening) in all POMC participants, and nausea and vomiting were also seen. There were no serious treatment-related side effects in either trial.
What it doesn’t show
Both trials were very small, open-label and had no comparison group for the main 1-year result, and hunger was measured only in people who responded early. The trials were funded by Rhythm Pharmaceuticals.
The paper
Clément et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020.
The compound
More studies on Setmelanotide
- Setmelanotide: injection-site reactions in 96% in pooled trialsMeta-analysis · people · 2026
- Setmelanotide: 16.5% BMI drop at 52 weeks in hypothalamic obesityRandomized trial · people · 2026
- Setmelanotide: patients reported less hunger, more energy in TRANSCENDClinical trial · people · 2026
- Setmelanotide: mean BMI fell 18% at 52 weeks in ages 2-5 (VENTURE)Clinical trial · people · 2025
- Setmelanotide: 15% mean BMI drop at 16 weeks in hypothalamic obesityClinical trial · people · 2024
- Setmelanotide: quality of life rose after 52 weeks in Bardet-BiedlClinical trial · people · 2023
- Every study on Setmelanotide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.